title: Endpoints in advanced breast cancer: methodological aspects & clinical implications.
abstract: Breast cancer is an increasingly important public health problem in developing countries, with disproportionately high mortality. The increasing availability of active agents against advanced breast cancer makes the development of novel treatments and their choice in clinical practice progressively more complex. Furthermore, there is often a tension between the adequacy of endpoints used in clinical trials and the clinician's aim of improving survival and quality of life, the two most important therapeutic goals in advanced breast cancer. However, overall survival (OS) is no longer a suitable indicator of treatment efficacy within clinical trials in settings for which effective subsequent-line therapy exists. Conversely, progression-free survival (PFS) currently represents the most sensitive parameter to assess the efficacy of a new drug or combination in such settings. When coupled with a favourable toxicity profile and cost, the demonstration of an improved PFS may be enough evidence for the superiority of a treatment. Despite arguments favouring the use of PFS as a primary endpoint in clinical trials, clinicians who need to make sense of the available literature may be reluctant to use PFS as an indicator of clinical benefit when deciding among different therapeutic strategies for their patients. This choice is further complicated if one fails to distinguish between the use of an efficacy parameter as an indicator of therapeutic objective for individual patients and as a clinical trial endpoint. This brief review aims at helping clinicians in their daily need to interpret the literature and make informed treatment choices for patients with advanced breast cancer.
authors.affiliation: Dendrix Research, Sao Paulo, Brazil. everardo@dendrix.com.br
authors.forename: Everardo D
authors.initials: ED
authors.lastname: Saad
mesh_terms: D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality*; D003362:Cost-Benefit Analysis / Q000191:economics; D018572:Disease-Free Survival; D023381:Endpoint Determination / Q000379:methods; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D016588:Anticarcinogenic Agents
references.citation: Eur J Cancer Clin Oncol. 1988 Oct;24(10):1567-72
references.pmid: 3208800
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: J Natl Cancer Inst. 2007 Mar 21;99(6):428-32
references.pmid: 17374832
references.citation: J Clin Oncol. 1999 Feb;17(2):485-93
references.pmid: 10080589
references.citation: Int J Technol Assess Health Care. 2008 Fall;24(4):371-83
references.pmid: 18828930
references.citation: J Natl Cancer Inst. 2010 Feb 24;102(4):230-43
references.pmid: 20118413
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Clin Oncol. 1995 Apr;13(4):858-68
references.pmid: 7707112
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2874-80
references.pmid: 19414672
references.citation: Ann Oncol. 2009 Mar;20(3):460-4
references.pmid: 19095776
references.citation: Oncology (Williston Park). 2006 May;20(6 Suppl 5):5-9
references.pmid: 16773839
references.citation: J Clin Oncol. 2010 Apr 10;28(11):1958-62
references.pmid: 20194852
references.citation: Lancet Oncol. 2009 Apr;10(4):341-50
references.pmid: 19246242
references.citation: Eur J Cancer. 1997 Jan;33 Suppl 2:S3-7
references.pmid: 9166088
references.citation: Br J Cancer. 2005 Nov 28;93(11):1215-21
references.pmid: 16278665
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5218-24
references.pmid: 18024867
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5153-4
references.pmid: 18024861
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3490-6
references.pmid: 16849766
references.citation: J Thorac Oncol. 2007 Jun;2 Suppl 2:S51-8
references.pmid: 17589300
references.citation: J Clin Oncol. 2003 Apr 1;21(7):1404-11
references.pmid: 12663734
references.citation: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references.pmid: 10655437
references.citation: Semin Oncol. 2006 Feb;33(1 Suppl 2):S2-5
references.pmid: 16472711
references.citation: J Clin Oncol. 2003 May 15;21(10):2045-7
references.pmid: 12743164
references.citation: Cancer. 2008 Oct 15;113(8 Suppl):2353-8
references.pmid: 18837028
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1987-92
references.pmid: 18421050
references.citation: Haematologica. 2011 Aug;96(8):1106-12
references.pmid: 21546500
references.citation: Biostatistics. 2000 Mar;1(1):49-67
references.pmid: 12933525
references.citation: J Clin Oncol. 2011 Feb 20;29(6):755-60
references.pmid: 21263086
references.citation: Cancer. 2001 Jun 1;91(11):2033-8
references.pmid: 11391582